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Purpose: Pancreatic neuroendocrine tumors (PNET) are a rare subgroup of tumors. 
For PNETs, the predictive factors for survival and prognosis are not well known. 
The purpose of our study was to evaluate the predictive factors for survival and dis-
ease progression in PNETs. Materials and Methods: We retrospectively analyzed 
37 patients who were diagnosed with PNET at Severance Hospital between No-
vember 2005 and March 2010. Prognostic factors for survival and disease progres-
sion were evaluated using the Kaplan-Meier method. Results: The mean age of the 
patients was 50.0±15.0 years. Eight cases (21.6%) were described as functioning 
tumors and 29 cases (78.4%) as non-functioning tumors. In univariate analysis of 
clinical factors, patients with liver metastasis (p=0.002), without resection of prima-
ry tumors (p=0.002), or American Joint Committee on Cancer/Union for Interna-
tional Cancer Control (AJCC/UICC) stage III/IV (p=0.002) were more likely to 
demonstrate shorter overall survival (OS). Patients with bile duct or pancreatic duct 
invasion (p=0.031), sized-lesions larger than 20 mm (p=0.036), liver metastasis 
(p=0.020), distant metastasis (p=0.005), lymph node metastasis (p=0.009) or with-
out resection of primary tumors (p=0.020) were more likely to demonstrate shorter 
progression-free survival (PFS). In multivariate analysis of clinical factors, bile duct 
or pancreatic duct invasion [p=0.010, hazard ratio (HR)=95.046] and tumor loca-
tion (non-head of pancreas) (p=0.036, HR=7.381) were confirmed as independent 
factors for predicting shorter PFS. Conclusion: Patients with liver metastasis or 
without resection of primary tumors were more likely to demonstrate shorter OS. 
Patients with bile duct or pancreatic duct invasion or tumors located at body or tail 
of pancreas were more likely to demonstrate shorter PFS.
Key Words:   Pancreatic neuroendocrine tumor, prognostic factor, liver metastasis, 
bile duct invasion, pancreatic duct invasion, location of tumor
INTRODUCTION
Pancreatic neuroendocrine tumors (PNETs), one of the rarest neoplasms, occur in 
fewer than one in 100000 people per year and represent 1-2% of all pancreatic tu-
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The clinical and laboratory data of patients were obtained 
from a retrospectively enrolled database of the patients. As 
candidate predictive factors for survival or disease progres-
sion, clinicopathological parameters, including patient gen-
der, age, tumor size, location, endocrine function, duct inva-
sion, resection of primary tumor, distant metastasis, lymph 
node metastasis, were investigated from a database of the 
enrolled patients. Diagnosis of PNET was confirmed by pa-
thologists via immunohistochemical staining (chromogranin 
A, synaptophysin), of a surgical specimen or biopsy sample.
Data analysis and statistical considerations
The primary end points were overall survival (OS) and pro-
gression-free survival (PFS). OS was calculated from the 
date of diagnosis until death from any cause or the patient’s 
last visit to the hospital. PFS in cases of resected tumors was 
calculated from the date of operation until the date of recur-
rence or the day of the last radiological evaluation (comput-
ed tomography or magnetic resonance imaging). PFS in cas-
es of unresected tumors was calculated from the date of 
diagnosis until the date of radiological evaluation, demon-
stration of tumor size increase, or the day of the last radio-
logical evaluation.
For univariate analysis, OS and PFS were calculated using 
Kaplan-Meier methods. For multivariate analysis, OS and 
PFS were calculated using the Cox regression method with a 
95% confidence interval. All analyses were performed with 
the SPSS statistical program (version 18.0; SPSS Inc., Seoul, 
Korea). A p-value of less than 0.05 was considered statistical-
ly significant.
 
RESULTS
 
Baseline characteristics of patients
The baseline demographic and clinical characteristics are 
summarized in Table 1. The patient population included 17 
men and 20 women, and the mean age of the patients was 
50.0±15.0 years. The most common clinical symptom was 
hypoglycemia (62.5%) in functioning tumors, but in non-
functioning tumors, 69.0% had no specific symptoms. Tu-
mor size ranged from 6 to 100 mm (average 28.08±19.29). 
Eight cases (21.6%) were listed as functioning tumors and 
29 cases (78.4%) as non-functioning tumors. Five patients 
(14%) had bile duct or pancreatic duct invasion, confirmed 
by imaging study (4 patients) or pathologic findings (1 pa-
tient) (Fig. 1). A total of 13 patients (35.1%) had distant 
mors.1 PNETs arise in all ages with a peak incidence be-
tween 30 and 60 years.1 Their incidence is thought to be in-
creasing over the past 20 years.2 During the 1980s and 
1990s, the term “carcinoid” was used, but this term was 
confusing for pathologists and clinicians. Since 2000, the 
terms “neuroendocrine tumor” and “neuroendocrine carci-
noma” have been introduced to describe neuroendocrine tu-
mors of the gastroentero-pancreatic system.3 
PNETs can be classified as functional or non-functional tu-
mors based on symptoms and endocrinologic laboratory 
tests.4 Functional PNETs secrete biologically active peptides, 
such as insulin, gastrin, glucagon, somatostatin, and vasoac-
tive intestinal polypeptides.4 Most functional tumors cause 
glycemic symptoms, such as hypoglycemia, but most non-
functional tumors are found by chance. PNETs can be spo-
radic or may be part of genetic syndrome, such as multiple 
endocrine neoplasia type 1 syndrome, von Hippel-Lindau 
disease, neurofibromatosis type 1, and tuberous sclerosis.3 
Approximately 60% of patients with PNET have been re-
ported to have liver metastasis at presentation. However, 
the slow growth pattern of PNET along with improvement 
in the methods of pre- and intra-operative tumor localiza-
tion, more aggressive treatments, including surgical inter-
ventions, have lead to better outcomes.3 Even though pa-
tients with PNET often have liver metastasis, 5-year survival 
can exceed 80% with liver resection or resection of the pri-
mary tumor and multimodal medical therapy.5 On the other 
hand, a much poorer 5-year survival of 29% has been re-
ported among groups in which primary tumors were not re-
sected.6
There have been some reports concerning the prognostic 
factors for predicting survival and disease progression of 
PNETs. Functional status, primary mass size, resectability, 
lymph node metastasis, distant metastasis, and location of 
tumor have been reported as prognostic factors.7-9 Up to 
now, prognostic factors have been inconclusive, because 
there are no consistent prognostic factors.
The aim of our study was to evaluate the prognostic factors 
for predicting survival and disease progression in PNETs. 
MATERIALS AND METHODS
　　　
Patients
Thirty seven patients diagnosed with PNET at Severance 
Hospital, Yonsei University, in Seoul, South Korea, between 
November 2005 and March 2010, were enrolled in this study. 
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Control (AJCC/UICC) staging, there were 21 (56.8%), 6 
(16.2%), 0 (0%), 10 (27.0%) cases of stages I, II, III, and 
IV tumors, respectively. According to European Neuroen-
docrine Tumors Society (ENETS) staging, there were 16 
(43.2%), 6 (16.2%), 5 (13.5%), 10 (27.0%) cases of stages 
metastasis. Among them, 10 patients (27%) had liver me-
tastasis. Twelve patients (32%) were positive for lymph 
node metastasis. There were 25 patients (68%) with tumors 
located at the head of the pancreas. According to American 
Joint Committee on Cancer/Union for International Cancer 
Table 1. Demographic and Clinical Characteristics of the 
Study Population
Characteristics (n=37) Total (%)
Age (mean±SD) 50±15
Gender
    Male 17 (45.9)
    Female 20 (54.1)
Symptom
    Functioning group (n=8) 
        Asymptomatic   2 (25.0)
        Hypoglycemia   5 (62.5)
        Galactorrhea   1 (12.5)
    Non-functioning group (n=29)
        Asymptomatic 20 (69.0)
        Abdominal pain   4 (13.8)
        Weight loss   2 (6.9)
        Jaundice   1 (3.4)
        Diarrhea   1 (3.4)
        Constipation   1 (3.4)
Size (mm) (mean±SD) 28.08±19.29
Location
    Head 25 (68)
    Body   7 (18.9)
    Tail   5 (13.5)
Distant metastasis 13 (35.1)
Site of metastasis
    Liver 10 (27)
    Peritoneum   1 (2.7)
    Stomach   1 (2.7)
    Adrenal gland   1 (2.7)
Ductal invasion   5 (14) 
    Bile duct invasion   2 (5.4) 
    Pancreatic duct invasion   3 (8.1)
Multicentricity   4 (10.8)
Metastasis to LN 12 (32)
AJCC/UICC stage
    I 21 (56.8)
    II   6 (16.2)
    III   0 (0)
    IV 10 (27)
ENETS stage
    I 16 (43.2)
    II   6 (16.2)
    III   5 (13.5)
    IV 10 (27)
AJCC/UICC, American Joint Committee on Cancer/Union for International 
Cancer Control; ENETS, European Neuroendocrine Tumors Society.
Fig. 1. Evidence of bile or pancreatic duct invasion, confirmed by cholangi-
ography (A), CT (B), magnetic resonance cholangio pancreatography (C), 
and pathologic findings (D). 
A
B
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tumor without resection (p=0.002), with liver metastasis 
(p=0.002), or AJCC/UICC stage III/IV (p=0.002) were 
more likely to demonstrate shorter OS (Table 2). Without 
liver metastasis, the 5-year survival rate was 96.3%, but it 
was 60% for the group with liver metastasis (Fig. 2A). If the 
primary tumors were resected, the 5-year survival rate was 
96.3%, where as it was 60% for the group in which primary 
tumors were not resected (Fig. 2B). 
Prognostic factors related to progression-free survival 
(PFS)
As of March 2010, 9 patients (24.3%) showed disease pro-
gression. The cumulative progression free survival was 89.2% 
at 1 year and 81.1% at 2 years. Median progression free sur-
vival could not be calculated because patients who experi-
enced disease progression did not amount to 50% of all pa-
tients. Univariate analysis of clinical factors showed that 
patients with bile duct or pancreatic duct invasion (p=0.031), 
tumor size larger than 20 mm (p=0.036), liver metastasis 
(p=0.020), distant metastasis (p=0.005), lymph node metasta-
I, II, III, and IV tumors. The mean follow-up period was 
23.3±16.6 months (Table 1).
Prognostic factors related to overall survival (OS)
As of March 2010, 5 patients (13.5%) died. The cumulative 
survival rate was 94.6% at 1 year and 91.9% at 2 years. 
Univariate analysis of clinical factors showed that primary 
Table 2. Univariate Analysis of Clinical Factors Associated 
with Overall Survival
Factor OS p value
Age (%) 0.623
    >50 44.935
    <50 47.698
Gender (%) 0.785
    Male 46.951
    Female 45.835
Size (%) 0.318
    ≥20 mm 42.745
    <20 mm 51.219
Location (%) 0.621
    Head 45.811
    Non-head 49.327
Function of tumor 0.136
    Function NA*
    Non-function NA*
Ductal invasion 0.691
    Yes NA*
    No NA*
Treatment of primary tumor 0.002
    Resection 53.091
    No resection 30.575
Liver metastasis 0.002
    Yes 30.575
    No 53.091
Distant metastasis except liver 0.325
    Yes 30.000
    No 48.331
Lymph node metastasis 0.071
    Yes 51.290
    No 35.257
AJCC/UICC stage 0.002
    I/II 53.091
    III/IV 30.575
ENETS stage 0.050
   I/II 52.524
   III/IV 38.149
OS, overall survival; NA, not applicable; AJCC/UICC, American Joint Com-
mittee on Cancer/Union for International Cancer Control; ENETS, European 
Neuroendocrine Tumors Society.
*OS was not available because survival rate was 100% in the group with 
functioning tumors and the group without duct invasion.
Fig. 2. (A) Disease-specific survival comparing patients with liver metasta-
sis and those without liver metastasis (p=0.002, univariate analysis). (B) 
Disease-specific survival comparing patients who underwent definitive re-
section of the primary tumor and those who did not (p=0.002, univariate 
analysis).
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Treatment modality
Surgical resection was performed in 27 patients. Among 
them, R0 resection was performed in 24 patients, all of 
which were still alive without recurrence. Surgical methods 
consisted of pylorus preserving pancreatoduodenectomy 
(n=7), distal pancreatectomy (n=9), enucleation (n=8), cen-
tral pancreatectomy (n=1), total pancreatectomy (n=1), or 
wedge resection (n=1). The other treatment options that 
were performed included concurrent neoadjuvant chemora-
diotherapy (n=3), palliative chemotherapy (n=6), transarte-
rial chemoembolization (n=2), transarterial chemoinfusion 
(n=1), or somatostatin analog (n=3).
DISCUSSION
Although 64.3% of gastroentero-pancreatic endocrine tu-
mors present metastasis at diagnosis, the 5-year survival is 
up to 77.5%.10 For pancreatic sites, poor differentiation and 
distant extra-hepatic metastasis have been reported as ma-
jor negative prognostic factors.10 Han, et al.7 reported that 
large PNETs, regardless of their functional status, were 
more likely to be associated with malignancy and a predic-
tor of worse survival. Paik, et al.8 demonstrated that resec-
tion of primary tumors in patients with PNET was associat-
ed with improved survival regardless of tumor stage. Kang, 
et al.9 reported that non-functioning tumors were more like-
ly to show recurrence. In our report, patients with liver me-
tastasis or without resection of primary tumors had shorter 
overall survival. Patients with bile duct or pancreatic duct 
invasion or tumors located in the body or tail of the pancre-
as were more likely to demonstrate shorter PFS. We as-
sumed that tumors located at the body or tail of the pancre-
as are less likely to present symptoms, so that tumors are 
found at advanced stages and are more likely to show dis-
ease progression. But, in our data, there was no definite dif-
ference in tumor stages between the two groups [ENETS 
stage III, IV: 40% (head) vs. 41.7% (non-head)].
As for diagnostic tools of PNETs, Chromogranin A ap-
pears to be the most useful serum marker for the diagnosis, 
staging and monitoring thereof.11 Chromogranin A is gain-
ing acceptance as a serum marker for neuroendocrine tu-
mors.12 In our report, almost all patients were diagnosed by 
positive chromogranin A staining, but serum tests for chro-
mogranin A was not performed. EUS is of high value for 
localizing primary lesions, and EUS-guided FNA can accu-
rately diagnose and predict prognoses based on cytopatho-
sis (p=0.009), without resection of primary tumor (p=0.020), 
AJCC/UICC stage III/IV (p=0.020), or ENETS stage III/IV 
stage (p=0.009) were more likely to demonstrate shorter PFS 
(Table 3). Multivariate analysis for prognostic factors demon-
strated that bile duct or pancreatic duct invasion [p=0.010, 
hazard ratio (HR)=95.046], and tumor location (non-head 
portion of pancreas) (p=0.036, HR=7.381) were significant 
factors for predicting shorter PFS (Table 4) (Fig. 3).
Table 3. Univariate Analysis of Clinical Factors Associated 
with Progression Free Survival
Factor PFS p value
Age (%) 0.891
    >50 34.848
    <50 36.127
Gender (%) 0.389
    Male 31.190
    Female 39.195
Size (%) 0.036
    ≥20 mm 29.038
    <20 mm 47.133
Location (%) 0.126
    Head 40.187
    Non-head 26.857
Function of tumor 0.354
    Function 38.740
    Non-function 34.569
Ductal invasion 0.031
    Yes 11.683
    No 38.637
Treatment of primary tumor 0.020
    Resection 42.404
    No resection 24.178
Liver metastasis 0.020
    Yes 42.404
    No 24.178
Distant metastasis except liver 0.005
    Yes 15.389
    No 40.057
Lymph node metastasis 0.009
    Yes 20.508
    No 42.070
AJCC/UICC stage 0.020
    I/II 42.404
    III/IV 24.178
ENETS stage 0.009
    I/II 45.407
    III/IV 25.555
PFS, progression free survival; AJCC/UICC, American Joint Committee on 
Cancer/Union for International Cancer Control; ENETS, European Neuro-
endocrine Tumors Society.
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intermediate grade), and 3 (neuroendocrine carcinoma) in 
an attempt to predict natural history from pathology re-
ports.4 In 2006, Rindi, et al.15 introduced a four stage TNM 
classification for PNETs, which has subsequently been ad-
opted by the ENETS. In 2010, the new AJCC/UICC TNM 
staging for PNETs was proposed distinguishing between 
localized tumors (stage I), locally advanced resectable tu-
mors (stage II), locally advanced unresectable tumors (stage 
III), and distantly metastasized tumors (stage IV).16 In our 
study, we were able classify PNETs by AJCC/UICC TNM 
staging, but we could not classify PNETs based on histo-
logic factors (WHO classification) due to insufficient data. 
From now on, PNETs need to be diagnosed based on both 
AJCC/UICC TMN staging and histologic findings (tumor 
differentiation, Ki-67 index, mitotic rate) through detailed 
data collection.
In contrast to our study, some articles reported that a 
small and pathologically benign nature did not predict a 
good prognosis in PNETs, so curative resection should be 
considered initially, even in cases of incidental PNETs.8 
Even in patients with PNET metastatic lesions, resection of 
primary tumors should be considered for reasonable opera-
tive candidates.17 In particular, resection of primary PNETs 
logic examination with immunocytochemistry. Somatosta-
tin receptor scintigraphy is a very sensitive procedure for 
diagnosing gastrinomas but not insulinomas. Computed to-
mography, ultrasonography and magnetic resonance imag-
ing are primarily useful for visualizing metastasis, which 
are able to predict prognoses.13 Cholangiography can be 
useful for evaluating bile duct invasion. Cholangiography 
was performed and was helpful in recognizing bile or pan-
creatic duct invasion, which was confirmed as a significant 
prognostic factor in our study. Although EUS-guided FNA 
was performed, it was not helpful in predicting prognoses, 
because most of patients’ data did not include Ki-67 index 
and mitotic rate. Further evaluation, such as mitoses mea-
surement and Ki-67 labeling, will be needed for predicting 
more reliable prognoses. 
Previous classification systems make a distinction be-
tween low and high-grade malignant NETs, but could not 
differentiate further prognosis. In contrast, according to tu-
mor stage and Ki-67 index, new TNM classification can dif-
ferentiate prognosis significantly.14 Also, according to size, 
mitoses, invasiveness, and Ki-67 labeling, recent WHO 
classification classifies PNETs into grades 1 (neuroendo-
crine neoplasm, low grade), 2 (neuroendocrine neoplasm, 
Fig. 3. (A) Disease-specific recurrence or progression comparing patients with duct invasion and those without duct invasion [p=0.010, HR=95.046 (3.857-
2341.986), multivariate analysis]. (B) Disease-specific recurrence or progression comparing patients with tumors in the head of pancreas and those not 
within the head of the pancreas [p=0.036, HR=7.381 (1.143-47.652), multivariate analysis].
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Table 4. Multivariate Analysis of Risk Factors for Progression Free Survival
Variables p value HR
95% CI
Lower Upper
Size 0.273   4.769 0.291     78.035
Ductal invasion 0.005 95.046 3.857 2341.986
Treatment of primary tumor 0.597   1.906 0.174     20.850
Distant metastasis except liver 0.350   3.421 0.259     45.130
Location (non-head of pancreas) 0.036   7.381 1.143     47.652
Lymph node metastasis 0.099   4.915 0.742     32.563
HR, hazard ratio; CI, confidence interval.
Tak Geun Oh, et al.
Yonsei Med J   http://www.eymj.org   Volume 53   Number 5   September 2012950
In conclusion, patients with bile duct or pancreatic duct 
invasion or tumors located at non-head portions of the pan-
creas or without resection of primary tumor should be mon-
itored carefully. But, because PNETs is a rare subgroup of 
tumor, we need more time and enough histopathologic data 
such as mitotic count and Ki-67 index for reliable prognos-
tic prediction. 
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